Skip to main content
Caplight Logo









Allermi

Allermi

Private
San Francisco, CaliforniaHealthcare & Life Scienceshttps://www.allermi.com/

Last Round

Seed

Mar 16, 2023

Total Funding Raised

$4.75M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Allermi is a healthtech company that provides a direct-to-consumer telehealth service for customized prescription nasal sprays to treat allergy symptoms.

Sector

Healthcare & Life Sciences

Verticals

Telemedicine, D2C Brands, Subscription Commerce, Patient Engagement

Business Model

B2C

Customer Profile

Hardware + Subscription

AI Layer

Non-AI

Keywords

compounded nasal sprayprescription nasal spraytelehealthallergy reliefdirect-to-consumertelemedicinecustom allergy medicationpersonalized medicineallergic rhinitis treatmentDTC telehealthsubscription commercecompounded medicationdirect-to-patientonline consultationHSA/FSA eligible

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Allermi Comparables

Compare Allermi with similar companies based on industry and business-model similarity.

Allermi comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Nectar
85%
Curex
81%
Wyndly
78%

Allermi Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedMar 16, 2023
Pre SeedSep 8, 2022

Key People

Founding team and executive leadership

Shuba Iyengar

Co-Founder & CMO At Allermi

Founding Team

Daniel Zakowski

Chief Executive Officer

Executive Team

David Gilmour

Chief Technology Officer

Executive Team

Allermi Investors

Notable investors and investment history

Allermi investors
InvestorRounds
FourSight Capital PartnersSeed
Lucas Venture GroupPre Seed
Nelstone VenturesSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors increased 41% MoM.

  • May 18, 2026

    Monthly visitors increased 37% MoM.

Allermi Filings

Explore SEC and related filing metadata, where available.

Allermi filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Allermi's valuation, stock price, and market status.

Is Allermi a public or private company?

Allermi is a private company.

What is the current stock price of Allermi?

Allermi is a private company with no public stock price. No recent secondary market data is available.

How much is Allermi worth (valuation)?

Valuation information for Allermi is not publicly available.

Can I buy Allermi stock?

Allermi shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Allermi's last funding round?

Allermi's most recent funding round was Seed on March 16, 2023.

Who are the main investors in Allermi?

Key investors in Allermi include Lucas Venture Group, Nelstone Ventures.

Will Allermi IPO soon?

No public IPO plans have been announced for Allermi.

How can I track Allermi secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Allermi's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSan Francisco, California
Employee Range19
Year Founded2021
Last FundingMar 16, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?